



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.


다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#) 

**Inhibition of CK2 to overcome
paclitaxel resistance in gastric cancer**

Minkyu Jung

Department of Medicine

The Graduate School, Yonsei University

Inhibition CK2 to overcome paclitaxel resistance in gastric cancer

Directed by Professor Sun Young Rha

The Doctoral Dissertation

submitted to the Department of Medicine,

the Graduate School of Yonsei University


in partial fulfillment of the requirements for the degree of

Doctor of Philosophy


Minkyu Jung

December 2016

This certifies that the Doctoral
Dissertation of Minkyu Jung is approved.



Thesis Supervisor: Sun Young Rha



Thesis Committee Member#1: Dong Bok Shin



Thesis Committee Member#2: Sahng Wook Park



Thesis Committee Member#3: Ki-Chul Hwang



Thesis Committee Member#4: Jae-Ho Cheong

The Graduate School
Yonsei University

December 2016

ACKNOWLEDGEMENTS

This page is dedicated to my gratitude and respect for those who helped me complete my thesis.

First of all, I'd like to give my sincere thanks to my enthusiastic mentor, prof. Sun Young Rha. My PhD has been an amazing experience and I thank professor Rha wholeheartedly, not only for her tremendous academic support, but also for giving me opportunities and encouragement. I also appreciate the advice of the committee members, prof. Dong Bok Shin, prof. Sahng Wook Park, prof. Ki-Chul Hwang, and prof. Jae-Ho Cheong for their critical comments, which strengthened my dissertation after the necessary improvements according to their comments. I would like to express my appreciation to Kyu Huyn Park, Tae Soo Kim, and Hyun Myoung Kim for his contribution to help my research.

I wish to send my appreciation and boundless love to parents-in-law, sister, brother, sisters-in-law. Special thanks are also given to Young Ok Kim for her constant faith as my wife, and my lovely son, Soobin, and daughter. Eunbin, for almost unbelievable support. Finally, I really appreciate my Heavenly Father, my God, who made me who I am today. They are the most important people in my world and I dedicate this thesis to them.

<TABLE OF CONTENTS>

ABSTRACT	1
I. INTRODUCTION.....	3
II. MATERIALS AND METHODS.....	6
1. Clinical specimens and chemotherapy protocol.....	6
2. Immunohistochemical analysis of CK2 and phosphorylated-AKT.....	6
3. Cell culture and reagents.....	8
4. Cell growth inhibition assay.....	9
5. Detection of CK2 activity in cell lysates	10
6. CK2 RNA extraction	10
7. Cell cycle analysis	11
8. Western blot analysis	12
9. Statistical analysis.....	13
III. RESULTS	15
1. Patient characteristics	15
2. Expression of CK2 and pAKT in GC patients	16

3. Association between CK2 and p-AKT expression and paclitaxel response	18
4. Association between CK2 and p-AKT expression and patients survival following paclitaxel therapy	19
5. Paclitaxel sensitivity in 49 GC cell lines	21
6. Association between CK2 expression and paclitaxel sensitivity	23
7. Association between CK2 expression and CX-4945 sensitivity in GC cells.....	25
8. Synergistic effect of paclitaxel and CX-4945 on proliferation of paclitaxel resistant SNU-1 cells.....	28
9. Effects of paclitaxel combined with CX-4945 on CK2 expression, PI3K/AKT signaling, and apoptosis in SNU-1 cells	30
IV. DISCUSSION	33
V. CONCLUSION	36
REFERENCE	37
ABSTRACT (IN KOREAN).....	46
PUBLICATION LIST.....	47

LIST OF FIGURES

Figure 1. CK2 and p-AKT protein expression in tumor tissue from gastric cancer patients·····	16
Figure 2. Kaplan-Meier survival curve according to CK2 expression·····	19
Figure 3. Antiproliferative effect of paclitaxel against 49 gastric cell lines ·····	21
Figure 4. Association between CK2 expression and paclitaxel sensitivity ·····	22
Figure 5. Association between CK2 expression and CX-4945 sensitivity ·····	25
Figure 6. Synergistic antiproliferative effects of paclitaxel and CX-4945 in SNU-1 cells·····	28
Figure 7. Cell cycle analysis of paclitaxel and CX-4945 in SNU-1 cells·	29
Figure 8. Effects of CX-4945 combined with paclitaxel on the CK2 expression, PI3K/AKT signaling, and apoptosis in SNU-1 cells ······	30

LIST OF TABLES

Table 1. Patient clinicopathologic characteristics	15
Table 2. Patient response according to CK2a and p-AKT expression ...	18

ABSTRACT

Inhibition of CK2 to overcome paclitaxel resistance in gastric cancer

Minkyu Jung

Department of Medicine,

The Graduate School, Yonsei University

(Directed by Professor Sun Young Rha)

Despite advances in treatment, gastric cancer (GC) remains among the most fatal malignancies. Paclitaxel has been used treatment for GC, however, it has limited clinical efficacy owing to drug resistance development. Casein kinase (CK) 2 activation has been implicated in the proliferation of various tumor types and resistance to chemotherapy. Herein, we investigated the mechanistic basis for the association between CK2 activation and paclitaxel resistance. CK2 expression was evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded tumor specimens from 59 advanced GC patients treated with paclitaxel as second-line therapy. Patients with high CK2 expression (29/59, 39%) showed lower disease control rate (47.7 % vs. 72.3 %, $p=0.017$) and shorter progression-free

survival (2.8 vs. 4.8 months, $p=0.009$) than patients with low expression.

CK2 protein expression was associated with sensitivity to paclitaxel in 49 GC cell lines. In SNU-1 line which showed paclitaxel resistance, high CK2 expression, and sensitivity to the CK2 inhibitor, 5-[(3-chlorophenyl)amino]-benzo[c]-2,6 naphthyridine-8-carboxylic acid (CX-4945), combination therapy with CX-4945 and paclitaxel exerted synergistic antiproliferative effects and inhibited of down signaling of phosphatidylinositol 3-kinase/AKT signaling. These results demonstrate that CK2 activation is related to paclitaxel resistance and that CX-4945 in combination with paclitaxel could be a treatment of choice for paclitaxel resistance in GC

Keywords: gastric cancer, paclitaxel, drug resistance, casein kinase II

Inhibition of CK2 to overcome paclitaxel resistance in gastric cancer

Minkyu Jung

Department of Medicine,

The Graduate School, Yonsei University

(Directed by Professor Sun Young Rha)

I. INTRODUCTION

Gastric cancer (GC) is major health problem worldwide, with high incidence and a poor prognosis.¹ Surgical resection in combination with adjuvant chemotherapy is the only curative treatment strategy for localized GC.^{2,3} However, recurrence is common, and for advanced or metastatic GC, chemotherapy is the first treatment option. Although clinical trials have sought to improve survival rates in GC patients, the median overall survival for metastatic disease is only about 1 year.⁴ Therefore, there is an urgent need for new strategies for improving treatment and survival.

Paclitaxel is effective for advanced GC treatment and has response rates in the range of 15% to 28% when used as monotherapy.⁵⁻⁹ It is most commonly used as second-line therapy in GC and showed good toxicity profiles in stomach cancer.¹⁰ However, the

median duration of paclitaxel response in GC is only about 3 months, and eventually patients have paclitaxel resistance.¹¹

The molecular mechanism underlying paclitaxel resistance is not well understood. Common mechanisms of drug resistance are overexpression of P-glycoprotein, and protein kinase C- α (PKC- α), as well as mitogen-activated protein kinase and phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathways.¹²⁻¹⁵ The PI3K/AKT pathways is specially activated following paclitaxel treatment, whereas PI3K inhibition sensitized tumors to paclitaxel and included cell death via mitotic arrest.¹⁶⁻¹⁸

Casein kinase (CK) 2 recently has proposed anticancer drug target is a constitutively active serine/threonine kinase that has pro-survival/anti-apoptotic functions.¹⁹ Given that CK2 is the overexpressed in multiple cancers and is implicated in many non-oncogenic processes required to sustain the cancer phenotype, its selective inhibition is an attractive strategy for cancer treatment.¹⁹⁻²¹ CK2 has been shown to phosphorylate AKT1 at Ser129 to promote cell survival by generating a constitutively active form of the protein.²² It also phosphorylates and stabilizes phosphatase and tensin homolog, thereby inhibiting its activity and inducing PI3K-mediated survival signaling and oncogenesis.²³ 5-[(3-chlorophenyl)amino]-benzo[c]-2,6 naphthyridine-8-carboxylic acid (CX-4945) is small

molecule, inhibitor of CK2 whose biological activity has been investigated *in vitro* and *in vivo*.²⁴ Key attributes of CX-4945 include potent inhibition of CK2 enzymatic activity and a highly selective kinase profile.²⁵ We speculated that paclitaxel resistance is associated CK2 activation and PI3K/AKT signaling, and that combining CK2 inhibition with paclitaxel chemotherapy can improve GC treatment efficacy.

To test this hypothesis, we investigated the association between CK2 expression and paclitaxel resistance, and evaluated whether CX-4945 in combination with paclitaxel can overcome paclitaxel resistance in GC.

II. MATERIALS AND METHODS

1. Clinical specimens and chemotherapy protocol

We used paraffin blocks of surgical specimens or endoscopic biopsied specimens of 59 advanced GC patients obtained before paclitaxel therapy at Yonsei University Health System (Seoul, Korea). All patients received paclitaxel ($175\text{mg}/\text{m}^2$ on day 1 every 3 weeks, or $70 - 80 \text{ mg}/\text{m}^2$ on day 1, 8, and 15 every 4 weeks) as a second-line chemotherapeutic agent. Paclitaxel was given until disease progression or occurrence of intolerable toxicities. Tumor assessments were performed every two cycles, and disease response was categorized as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumor (RECIST, v.1.1).²⁶

2. Immunohistochemical analysis of CK2 and phosphorylated-AKT

CK2 and phosphorylated (p-) AKT expression was evaluated by immunohistochemistry using anti-CK2 (Abcam, Cambridge, UK; 1:50) and anti-p-AKT (Cell Signaling Technology, Danvers, MA, USA, 1:40) antibodies. Sections cut at

a thickness of 4 μm and mounted on slides were deparaffinized in xylene, rehydrated and treated with 2.5% H_2O_2 for 10 min to block endogenous peroxidase activity. Heat-induced antigen retrieval was carried out for 2 min in 10 mmol/l citrate buffer (pH 7.0). After washing with phosphate-buffered saline (PBS), sections were incubated with primary antibody for 90 min at room temperature. After washing with PBS, sections were incubated at room temperature for 30 min with an anti-mouse secondary antibody followed by washing with PBS. Immunoreactivity was detected by incubation for 1 min with 0.5% 3,3-diaminobenzidine solution. After washing with PBS, the sections were stained with Harris hematoxylin, and three areas per slide were analyzed to confirm tissue diagnosis. The numbers of tumor cells with membrane and cytoplasmic labeling of CK2 and cytoplasmic and nuclear labeling of p-AKT were counted. Scoring was performed by a pathologist blinded to patients' clinical information. Protein expression was interpreted with weighted histoscore method.²⁷ The intensity of protein expression was scored as 0 (negative), 1 (light brown), 2 (brown), and 3 (dark brown). The final score was calculated as follows: $-(0 \times \% \text{ of negative cells}) + (1 \times \% \text{ of light brown cells}) + (2 \times \% \text{ of brown cells}) + (3 \times \% \text{ of dark brown cells})$. Patients were subdivided into following four groups based on the final score: 0 (negative), 1+ (final score; 1–100), 2+ (final score 101–200),

and 3 + (final score 201–300). High CK2 and p-AKT expression was defined as a score $\geq 1+$.

3. Cell culture and reagents

A total of 49 GC cell lines were used in this study. The YCC series was established by the Yonsei Cancer Center (Cancer Metastasis Research Center, Seoul, Korea) from the ascites or peripheral blood of advanced GC patients. Other cell lines were obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea) and the American Type Culture Collection (American Type Culture Collection, Manassas, VA, USA).

Cells were maintained in Roswell Park Memorial Institute-1640 medium (Lonza, Walkersville, MD, USA) or Eagle's minimal essential medium (Lonza, Walkersville, MD, USA) and supplemented with 10% fetal bovine serum (Omega Scientific, Tarzana, CA, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/l glutamine in a 5% CO₂-humidified atmosphere at 37°C. Cell lines were expanded and cryopreserved in liquid nitrogen in our laboratory.

CX-4945 was synthesized by and supplied without cost by Cylene Pharmaceuticals (San Diego, CA, USA). Paclitaxel was purchased from Sigma-Aldrich (St. Louis, MO,

USA).

4. Cell growth inhibition assay

Cell proliferation was evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded at the density of 5×10^3 cells into a 96-well plate and incubated at 37°C for 24 h. Paclitaxel and CX-4945 were serially diluted with medium and added to each well. After 72 h of incubation, 50 μ l (2 mg/ml) of the MTT solution was added, and followed by incubation for an additional 4 h. After centrifugation at $400 \times g$ for 10 min, the medium containing MTT was removed and the remaining MTT-formazan crystals were dissolved by adding 150 μ l of dimethylsulfoxide. After 10 min incubation with shaking, the absorbance at 570 nm was measured with a multi-well microplate read. Results are expressed as percentage cell survival, which was calculated with the following formula: $\frac{1}{4} [(mean\ absorbance\ of\ test\ wells - standard\ absorbance) / (mean\ absorbance\ of\ control\ wells - standard\ absorbance)] \times 100$. Control wells were treated with the medium alone (without the drug). At least 3 replicates were prepared for each treatment and the average of these data was used for data analyses. Synergy was assessed using the New Bliss Independence Model.²⁸

Combined percentage inhibition $Y_{ab, p}$ was predicted using the complete addition of probability theory as $Y_{ab, p} = Y_a + Y_b - Y_a Y_b$ (drug A at dose a inhibits Y_a % of tumor growth and drug B at dose b inhibits Y_b % of tumor growth). The observed combined percentage inhibition $Y_{ab, o}$ was then compared as $Y_{ab, p}$, $Y_{ab, o} > Y_{ab, p}$, $Y_{ab, o} = Y_{ab, p}$, and $Y_{ab, o} < Y_{ab, p}$ indicated that effects were synergistic, independent (additive), and antagonistic, respectively.

5. Detection of CK2 activity in cell lysates

GC lines were seeded in 6-well plates overnight, then collected at 80% confluence by scraping into ice-cold PBS. CK2 activity in cell lysates was determined using a CK2 kinase assay kit (CycLex Co., Nagano, Japan) according to the manufacturer's instructions.

6. CK2 RNA extraction

Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. First strand cDNA was synthesized from 2 μ g total cellular RNA with oligo (dT) using a cDNA synthesis kit (Fermentas, Hanover,

MD, USA). Quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed on a 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA) using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The primers used were as follows: CK2a, 5'-TGTCCGAGTTGCTTCCCGATACTT-3' and 5'-TTGCCAGCATACAACCCAAACTCC-3' and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 5'-CCATGGAGAAGGCTG GGG-3' and 5'-CAAAGTTGTCAT GGATGACC-3'. Relative copy number was determined using the comparative *Ct* method. GAPDH served as the internal control for normalization.

7. Cell cycle analysis

Cell cycling was evaluated by flow cytometry analysis of cells stained with propidium iodide (PI) (BD Biosciences, San Jose, CA, USA). SNU-1 cells were left untreated, or treated for 36 h with paclitaxel (0.1 or 1 μ M), CX-4945 (5 or 1 μ M) typsinized, fixed overnight with 70% ethanol at -20°C and incubated for 30 min in the dark at room temperature with 200 μ l PI solution. After washing with PBS, cells were resuspended in 500 μ l PBS analyzed on a FACS Calibur system (BD Biosciences, San Jose, CA, USA).

8. Western blot analysis

SNU-1 cells were washed twice in PBS, lysed in ice-cold buffer composed of 1% Nonidet P-40, 10% (v/v) glycerol, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2.5 mM EDTA, 100 μ M Na₃VO₄, 1% aprotinin, 1% leupeptin, and 1 mM perfluoro-1-butanesulfonyl fluoride for 30 min at 4°C and centrifuged 13,000 rpm for 20 min at 4°C. The supernatant was collected and total protein concentration was quantified by the Bradford assay and stored at -70°C until use. For western blotting, proteins were mixed with 5 × sample buffer and boiled at 95°C for 5 min, then resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis using 7.5% or 10% polyacrylamide gels, followed by transfer to a polyvinylidene difluoride membrane (GE Healthcare, Piscataway, NJ, USA) by electroblotting. The membrane was blocked with 5% skim milk for 1 h at room temperature and incubated overnight with primary antibodies against the following proteins: p-CK2 (pS/pTDXE, #8738), AKT (Ser473, #9272), p-AKT (Ser473, #4058), mammalian target of rapamycin (mTOR) (7C10, #2983), p-mTOR (Ser2448, #2971), p70S6K (#9202), p-p70S6K (Thr387, #9234), and cleaved PARP1 (Asp214, #9541) (all from Cell Signaling Technology); anti-p-AKT (Ser129, ab133458, Abcam, Cambridge, UK); and CK2 (1AD9, sc-12738, Santa Cruz

Biotechnology, Santa Cruz, CA, USA). Horseradish peroxidase-conjugated anti-mouse and -rabbit IgG (Santa Cruz Biotechnology) were used as secondary antibodies. The membrane was developed by enhanced chemiluminescence (GE Healthcare, Piscataway, NJ, USA). Anti-alpha tubulin antibody (#T6199; Sigma-Aldrich) was used as a loading control. Protein band signal intensities were quantitated with ImageJ software (National Institutes of Health, Bethesda, MD, USA).

9. Statistical analysis

Clinical characteristics and treatment outcomes of patients were compared according to CK2 expression with the χ^2 test and Fisher's exact test. Survival estimates were calculated using the Kaplan-Meier method. Progression-free survival (PFS) was calculated from the date chemotherapy was started to the earliest date of disease progression or death from any other cause. And overall survival (OS) was defined as the time from the start of paclitaxel treatment to death from any cause. Differences in PFS and OS according to CK2 and p-AKT expression were compared with the log-rank test. Significant effects between treatment groups or between treatment and control groups were evaluated with using the Mann-Whitney U test. Data were analyzed SPSS, v 23.0

(SPSS Inc., Chicago, IL, USA) and plots and curves were generated with Prism v.5

software (GraphPad Inc., San Diego, CA, USA).

III. RESULTS

1. Patient characteristics

A total of 59 patients for whom tumor tissue specimens were available for CK2 and p-AKT expression analysis were included in this study. The median age was 59 years (range, 53-68 years), and 62.7% was male. About 60% patients were underwent gastrectomy before paclitaxel treatment (Table 1), eight (13.6%) were positive human epidermal receptor 2 (HER2).


Table 1. Patients' clinicopathologic characteristics

Characteristics		Number	%
Age			
	Median	59	
	IQR	53-68	
Sex			
	Male	37	62.7
	Female	22	37.3
WHO classification			
	Adenocarcinoma well differentiated	6	10.2
	Adenocarcinoma moderately differentiated	15	25.4
	Adenocarcinoma poorly differentiated	26	44.1
	Signet ring cell	9	15.5
	Others	3	5.2
Prior gastrectomy			
	Yes	36	61
	No	23	39
HER2 status			
	Positive	8	13.6
	Negative	39	66.1
	Unknown	12	20.3
Disease			
	Measurable	30	62.7
	Non-measurable	22	37.3
Metastatic location			
	Distant Lymph node	16	27.1
	Liver	13	22
	Peritoneum	37	62.7
	Lung	3	5.1
	Bone	2	3.4

HER2, human epidermal receptor 2; IQR, interquartile range; WHO, World Health Organization

2. Expression of CK2 and p-AKT in GC patients

Median CK2 and p-AKT immunoreactivity scores were 50 (range, 0-210) and 110 (range, 0-270), respectively. At a cutoff score of 1+, CK2 and p-AKT expression was high in 23 (40%) and p-AKT in 40 (67.8%) of the 59 patients, respectively (Figure 1).






Figure 1. CK2 and p-AKT protein expression in tumor tissue from gastric cancer patients. (A) CK2 and (B) p-AKT immunoreactivity was graded as a) negative, b) weak (light brown), c) moderate (brown), or d) strong (dark brown). Original magnification: 200X, Scale bar: 50 μ m.

3. Association between CK2 and p-AKT expression and paclitaxel response

Response to paclitaxel was evaluated 56 of 59 patients. Two patients could not undergo a second cycle of chemotherapy due to decreased performance status, and one patient refused chemotherapy after the first treatment cycle. The overall response rate (ORR) was 10.2% and the disease control rate (DCR = CR + PR + SD) was 62.7%. There was no association between ORR or DCR and p-AKT expression. However, patients with

high CK2 levels had lower DCR (47.8% vs. 72.3%, $p = 0.017$) (Table 2).

Table 2. Response according to expression of CK2 and p-AKT

	All (%)	CK2			p-AKT		
		Positive (n=23)	Negative (n=36)	p-value	Positive (n=40)	Negative (n=19)	p-value
CR	0	0	0	0.004	0	0	0.295
PR	6 (10.2)	4 (17.4)	2 (5.6)		2 (5)	4 (21.1)	
SD	31 (52.5)	7 (30.4)	24 (66.7)		22 (55)	9 (47.4)	
PD	19 (32.2)	12 (52.2)	7 (19.4)		14 (35)	5 (26.3)	
NE	3 (5.1)	0	3 (8.3)		2 (5)	1 (5.3)	
ORR	6 (10.2)	4 (17.4)	2 (5.6)	0.181	2 (5)	4 (21.1)	0.077
DCR	37 (62.7)	10 (47.8)	26 (72.3)	0.017	24 (60)	13 (68.5)	0.503

CR, complete response; DCR, disease control rate; NE, not evaluable or not assessed; ORR, overall response rate; p-AKT, phosphorylated AKT; PD, progressed disease; PR, partial response; SD, stable disease

4. Association between CK2 and p-AKT expression and patients survival following paclitaxel therapy

In all patients, the median PFS and OS were 3.5 months [95% confidential interval (CI); 2.7 - 4.3 months] and 8.9 months (95% CI; 6.3 - 10.8 months), respectively. There was no difference in PFS according to age and sex, and no difference in PFS and OS according to p-AKT expression. However, PFS was longer in patients with low as

compared with high CK2 expression (median PFS, 4.1 vs. 2.8 months, $p = 0.009$). OS

was not associated with CK2 expression (Figure 2).




Figure 2. Kaplan-Meier survival curve according to CK2 expression. (A) PFS in 59

patients; the median values for patients with low and high CK2 expression were 4.1 months versus 2.8 months ($p=0.009$). (B) There was no difference of OS according to CK2 level.

5. Paclitaxel sensitivity in 49 GC cell lines

Since CK2 protein expression was associated with paclitaxel resistance in tumor tissue of gastric cancer patients, we investigated the association between paclitaxel sensitivity and CK2 expression in 49 gastric cancer cell lines. The antiproliferative effect of paclitaxel was evaluated with the MTT assay. The YCC-30 cell line was the most sensitive to paclitaxel treatment with half-maximal inhibitory concentration (IC₅₀) of 0.0003 μ M; in contrast, YCC-25, YCC-28, and YCC-33 cells were highly resistant to the effects of paclitaxel IC₅₀ ≥ 10 μ M. The cut-off level of paclitaxel sensitivity/resistance is 0.1 μ M Catalogue of Somatic Mutations in Cancer (<http://cancer.sanger.ac.uk/cosmic>). According to this value, 18 cell lines (36.7%) were resistant to paclitaxel (Figure 3).







Figure 3. Antiproliferative effect of paclitaxel against 49 gastric cell lines. GC cell lines (n = 49) were treated with increasing doses of paclitaxel and IC₅₀ was determined with the MTT assay. The most sensitive cell line was YCC-30 (IC₅₀ = 0.0003 μM), whereas SNU-1 cells showed the highest resistance (IC₅₀ = 7.2 μM). *Cutoff level for resistance to paclitaxel defined according to the Catalogue of Somatic Mutations in Cancer database.

6. Association between CK2 expression and paclitaxel sensitivity

We evaluated CK2 mRNA and protein expression, and CK2 activity in 49 GC cell lines.

Paclitaxel-resistant cell lines had higher CK2 protein expression than those that were sensitive to the drug ($p=0.041$, Figure 3A). However, neither CK2 mRNA nor activity was correlated with paclitaxel sensitivity (Figure 4B and 4C). p-AKT expression was not associated with paclitaxel resistance (Figure 4D).









Figure 4. Association between CK2 expression and paclitaxel sensitivity. (A) CK2 protein levels in 49 gastric cell lines were evaluated by western blotting and compared between paclitaxel-sensitive and -resistant cells. (B) CK2 mRNA expression was assessed by quantitative reverse transcription PCR and compared between paclitaxel-sensitive and -resistant lines. (C) CK2 kinase activity was evaluated by the CK2 kinase assay and compared between paclitaxel-sensitive and -resistant lines. (D) p-AKT expression was assessed by western blotting and compared between paclitaxel-sensitive and -resistant cell lines. The mRNA and protein levels were normalized to those of Jurkat cells. * $p < 0.05$; ns, not significant.

7. Association between CK2 expression and CX-4945 sensitivity in GC cells

We treated the GC cell lines with CX-4945 and found that the IC₅₀ ranged from 2.7 to >100 μM . The cell lines were divided into CX-4945-sensitive and -resistant groups, with a cut-off CX-4945 IC₅₀ of 10 μM . According to this value, 20 cell lines were sensitive to

CX-4945. High CK2 protein expression was correlated with CX-4945 sensitivity ($p = 0.058$); however, there was no association between CK2 mRNA or activity and CX-4945 sensitivity (Figure 5).







Figure 5. Association between CK2 expression and CX-4945 sensitivity. (A) CK2 protein levels in 49 gastric cell lines were evaluated by western blotting and compared between

CX-4945-sensitive and -resistant cells. (B) CK2 mRNA expression was assessed by quantitative reverse transcription PCR and compared between CX-4945-sensitive and -resistant lines. (C) CK2 kinase activity was evaluated by the CK2 kinase assay and compared between CX-4945-sensitive and -resistant lines. The mRNA and protein levels were normalized to those of Jurkat cells

8. Synergistic effect of paclitaxel and CX-4945 on proliferation of paclitaxel resistant SNU-1 cells

The above results indicated that CK2 expression was associated with paclitaxel resistance and that CX-4945 was effective in cell lines with CK2 protein expression. We therefore, speculated that combined treatment of paclitaxel and CX-4945 could overcome paclitaxel resistance. We tested our hypothesis by treating paclitaxel-resistant ($IC_{50} = 1.122 \mu M$, Figure 3), CX-4945-sensitive ($IC_{50} = 7.2 \mu M$) SNU-1 cells with paclitaxel (0.1 or 1 μM monotherapy), CX-4945 (5 or 10 μM monotherapy), or both (0.1 μM paclitaxel, and 5 or 10 μM CX-4945). The combination of both drug had synergistic inhibitory effect on cell proliferation relative to CX-4945 or paclitaxel monotherapy according to New Bliss Independence Model ($Y_{ab, o} = 0.767 > Y_{ab, p=0.478}$) (Figure 6)




Figure 6. Synergistic antiproliferative effects of paclitaxel and CX-4945 in SNU-1 cells. The additivity line is equivalent to the theoretical combined antiproliferative effects of drugs A and B [$\%A + \%B (100 - \%A/100)$] in which %A and %B are the percentages of cells killed by drugs A and B, respectively, at a given concentration. *28.9%.

We investigated whether paclitaxel, CX-4945, or their combination inhibited SNU-1 cell-cycle progression of SNU-1 by flow cytometry. The proportion of cells in G2/M phase was increased by concomitant treatment with both drugs (Figure 7). Notably, G2/M

arrest was markedly increased in these cells treated with paclitaxel combined with CX-4945.




Figure 7. Cell cycle analysis of paclitaxel and CX-4945 in SNU-1 cells. SNU-1 cells were treated with CX-4945 (5 or 10 μM), paclitaxel (0.1 or 1 μM), and paclitaxel (0.1 μM) combined with CX-4949 (5 or 10 μM) for 36 h, and cell cycle distribution was analyzed by flow cytometry. The fraction of cells in sub-G1, G0/G1, S, and G2/M phases of the cell cycle is shown. Combined treatment of paclitaxel and CX-4945 induced G2/M arrest

9. Effects of paclitaxel combined with CX-4945 on CK2 expression,

PI3K/AKT signaling, and apoptosis in SNU-1 cells

The effects of combined paclitaxel and CX-4945 treatment on CK2 expression, PI3K/AKT signaling, and apoptosis were analyzed by western blotting analysis in SNU-1 cells. CX-4945 decreased phosphorylation of CK2, AKT and downstream signaling protein p70S6K, while paclitaxel has opposite effect. CX-4945 combined

with paclitaxel decreased p-CK2, p-AKT, p-p70S6K expression. The effect of CX-4945 on apoptosis was also investigated by evaluating cleaved poly (ADP-ribose) polymerase (PARP)-1 protein expression. CX-4945 and paclitaxel monotherapy induced cleaved PARP-1 expression; this effect was potentiated by combination treatment with both drugs (Figure 8).




Figure 8. Effect of CX-4945 combined with paclitaxel on the CK2 expression,

PI3K/AKT signaling, and apoptosis in SNU-1 cells. SNU-1 cells were treated with vehicle, CX-4945 (5 or 10 μ M), paclitaxel (0.1 or 1 μ M), and paclitaxel (0.1 μ M) combined with CX-4949 (5 or 10 μ M) for 48h. Western blotting was conducted to assess AKT signaling

IV. DISCUSSION

In this study, we examined the relationship between CK2 expression and paclitaxel resistance in GC. CK2 is a ubiquitous serine/threonine kinase that regulates a variety of cellular processes including cell cycling, proliferation, and apoptosis.²⁹ CK2 overexpression is correlated with tumorigenesis in various types of cancer as well as with the degree of tumor invasion; more over, patients with elevated levels of CK2 had lower overall survival in surgically resected GC.^{21,30,31} Interestingly, CK2 was shown to exert anti-apoptotic effects via upregulation of AKT.²² Given that PI3K/AKT activation is associated with paclitaxel resistance, we speculated that CK2 is also related to paclitaxel resistance via the PI3K/AKT pathway in GC.^{16,17,32}

To test our hypothesis, we investigated CK2 expression in the tumor tissue of GC patients treated with paclitaxel as second-line chemotherapy. As predicted, CK2 overexpression was correlated with paclitaxel resistance. Patients with higher CK2 expression levels had significantly shorter survival and lower DCR from paclitaxel therapy as compared to those with low CK2 expression. The association of between CK2 expression and paclitaxel resistance was confirmed *in vitro* using GC cell lines.

CX-4945 is a potent and selective small-molecule inhibitor of CK2 that is active against

a broad range of malignancies, including breast, colon, pancreas, prostate, ovarian, and lung cancer.³³ The efficacy of CX-4945 against GC has been not previously reported. We identified 20 GC cell lines among 49 that were CX-4945 sensitive cell lines, with a CX-4945 IC50 cut-off level of 10 μ M. Cell lines with high CK2 protein expression trended to be sensitive to CX-4945. Combination treatment of SNU-1 which overexpress CK2 protein and show paclitaxel resistance, and CX-4945 sensitivity with paclitaxel and CX-4945 had a synergistic effect on proliferation relative to cell treated with either drug alone. Combination treatment and CX-4945 monotherapy also decreased the phosphorylation of CK2, AKT, and the downstream factor p70S6K, whereas paclitaxel monotherapy had the opposite effect. This suggests that PI3K/AKT activation by paclitaxel may contribute to paclitaxel resistance. Indeed, PI3K/AKT signaling was suppressed by CK2 inhibition, leading to cell cycle arrest and apoptosis.

Given our observation that CK2 activation is related with paclitaxel resistance, CX-4945 in combination with paclitaxel could be a treatment of choice in paclitaxel-resistant GC. However, the inhibition of CK2 to overcome paclitaxel resistance requires confirmation xenograft model before clinical trials are initiated. In addition, paclitaxel sensitivity must be evaluated, according to the different molecular subtypes of GC

which have been shown to be associated with distinct clinical outcomes^{34,35} Two genes, involved in tubulin processing-*tubulin gamma complex-associated protein 4* and *N-acetyltransferase 10*- were related to poor prognosis in the Stem-A subtype of ovarian cancer, which exhibits elevated microtubule activity and is sensitive to several microtubule polymerization-inhibiting drugs; such as vincristine and vinorelbine.³⁶ It is possible that GC subtype also have variable sensitivity to microtubule inhibitors.

V. CONCLUSION

The results presented here suggest that high CK2 expression is negative predictive marker for paclitaxel response in GC. Paclitaxel resistance was related to CK2 expression through the PI3K/AKT signaling pathway. Our findings suggested that CK2 inhibition with CX-4945 which induces G2/M cell cycle arrest and increases apoptosis by suppressing PI3K/AKT signaling in combination with paclitaxel can be effective against paclitaxel resistant GC.

REFERENCE

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet TJ, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357:1810-20.
3. Bang Y, Kim Y, Yang H, Chung HC, Park Y, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012;379:315-21.
4. Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, et al. Unmet needs and challenges in gastric cancer: the way forward. *Cancer Treat Rev* 2014;40:692-700.
5. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern

Cooperative Oncology Group (ECOG) results of protocol E1293. *Med Oncol* 1996;13:87-93.

6. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. *Am J Clin Oncol* 2000;23:341-4.

7. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. *Br J Cancer* 1994;70:380-3.

8. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. *Jpn J Clin Oncol* 2009;39:713-9.

9. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. *Gastric Cancer* 2002;5:90-5.

10. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol* 2013;31:4438-44.
11. Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014;15:1224-35.
12. Kim H, Park GS, Lee JE, Kim JH. A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells. *Br J Cancer* 2013;109:351-9.
13. Zhao L, Xu H, Qu J, Zhao W, Zhao Y, Wang J. Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC- α) with small interference RNA (siRNA) agents. *Asian Pac J Cancer Prev* 2012;13:3631-6.
14. Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J, et al. Enhancement of

paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. *Anticancer Res* 2009;29:261-70.

15. Liu Z, Zhu G, Getzenberg RH, Veltri RW. The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. *J Cell Biochem* 2015;116:1341-9.

16. Xu R, Nakano K, Iwasaki H, Kumagai M, Wakabayashi R, Yamasaki A, et al. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer. *Cancer Lett* 2011;306:151-60.

17. Sun H, Yu T, Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. *Cancer Lett* 2011;310:118-28.

18. Awasthi N, Yen PL, Schwarz MA, Schwarz RE. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. *J Cell Biochem* 2012;113:784-91.

19. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. *Biochim Biophys Acta* 2008;1784:33-47.
20. Wang J, Feng C, He Y, Ding W, Sheng J, Arshad M, et al. Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis. *Oncotarget* 2015;6:27700-13.
21. Lin K, Fang C, Chen Y, Li C, Chen S, Kuo C, et al. Overexpression of nuclear protein kinase CK2 Beta subunit and prognosis in human gastric carcinoma. *Ann Surg Oncol* 2010;17:1695-702.
22. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. *Cell Death Differ* 2005;12:668-77.
23. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. *J Biol Chem* 2001;276:993-8.

24. Cozza G, Pinna LA, Moro S. Protein kinase CK2 inhibitors: a patent review. *Expert Opin Ther Pat* 2012;22:1081-97.
25. Pierre F, Chua PC, O'Brien SE, Siddiqui JA, Bourbon P, Haddach M, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. *Mol Cell Biochem* 2011;356:37-43.
26. van Oosterom AT, Schrijvers D, Schriivers D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. *Anticancer Drugs* 1995;6:356-68.
27. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. *Histopathology* 2004;45:47-54.
28. Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data. *J Biomol Screen* 2014;19:817-21.
29. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular

decisions of life and death. *Biochem J* 2003;369:1-15.

30. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. *Oncogene* 2002;21:5280-8.

31. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells – a potential approach to cancer therapy. *Mol Cell Biochem* 2005;274:77-84.

32. Kim SH, Juhn YS, Song YS. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. *Ann N Y Acad Sci* 2007;1095:82-9.

33. Siddiqui JA, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. *Cancer Res* 2010;70:10288-98.

34. Cancer Genome Atlas Research Network. et al. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014;513:202-9.

35. Cristescu R, Nebozhyn M, Kim K, Ting JC, Wong SS, Liu J, et al. Molecular

analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.

Nat Med 2015;21:449-56.

36. Tan TZ, Miow QH, Huang RY, Wong MK, Ye J, Lau JA, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 2013;5:1051-66.

ABSTRACT (IN KOREAN)

위암에서 paclitaxel 저항 극복 방법으로서는 CK2의 억제 효과

<지도교수 라선영>

연세대학교 대학원 의학과

정민규

진행성 위암은 치료 발전에도 불구하고, 여전히 예후가 앞좋은 암종에 하나이다. 파클리탁셀은 위암의 주된 항암제 중에 하나이나, 저항기전으로 인해 그 효과는 제한적이다. 최근, Casein kinase 2 (CK2)의 활성화는 다양한 암종에서 종양의 증식과 연관되고, 항암제 저항성과 관계되는 연구가 보고되고 있다. 따라서, 본 연구는 위암에서, 파클리탁셀의 저항성과 CK2 활성화에 대해 조사하고자 하였다. 2차 약제로 파클리탁셀로 치료 받은 59명의 진행성 위암환자를 대상으로, 치료 전 종양조직을 이용하여 면역 화학 조직 염색법으로 CK2 발현을 조사하였다. CK2가 과발현 된 환자는 (29/59, 39%), CK2가 발현되지 않은 환자에 비해 질병 조절율이 통계학적으로 낮았으며 (47.7 % vs.

72.3 %, $p=0.017$), 무진행 생존율도 짧았다 (2.8 months vs. 4.8 months, $p=0.009$).

49 개의 위암 세포주를 이용하여 파클리탁셀 및 CK2 억제제인 CX-4945 에 대한 항증식효과를 조사한 결과 CK2 단백질의 과발현과 파클리탁셀의 저항성과 상관관계가 있었다. 49 개의 위암세포주 중에 파클리탁셀에 저항성이 있으며, CK2 단백질이 과발현을 보이며, CX-4945 에 민감한 세포 주인 SNU-1 세포주를 선택하여, 파클리탁셀과 CX-4945 와 병합 치료하였을 경우 항종양 상승효과가 있었으며, PI3K/AKT 경로를 통해 억제됨을 확인 하였다.

결론적으로, CK2 과발현은 위암에서 파클리탁셀의 저항성과 관련이 있었으며, paclitaxel 과 CK2 억제제인 CX-4945 를 병합치료는 파클리탁셀의 저항성을 극복하는 치료 방법이 될 수 있을 것이다.

핵심되는 말: 위암, 파클리탁셀, 약물 저항성, casein kinase II

PUBLICATION LIST

1. Kim HS, Shin S-J, Beom S-H, Jung M, Choi YY, Son T, et al. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. *Oncotarget* 2016;7:44608-20.
2. Lim SM, Kang B, Rha SY, Noh SH, Hyung WJ, Cheong J, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. *Ann Nucl Med* 2016;30:279-86.
3. Lee C, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. *Ann Surg* 2016;263:96-102.
4. Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, et al. Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. *Oncology* 2015;88:147-56.
5. Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, et al. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. *Oncology* 2015;88:76-85.

6. Park HS, Jung M, Kim H, An JY, Cheong J, Hyung WJ, et al. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. *Ann Surg Oncol* 2015;22:224-31.
7. Noh S, Jung J, Jung M, Kim TS, Park CH, Lim SJ, et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. *Hepatogastroenterology* 2011;58:2015-9.
8. Jung J, Jeung H, Jung M, Kim TS, Noh SH, Roh JK, et al. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. *Cancer Sci* 2010;101:2200-6.
9. Jung M, Jeung H, Lee SS, Park JY, Hong S, Noh SH, et al. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. *J Cancer Res Clin Oncol* 2010;136:517-26.
10. Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, et al. Prognosis of pN3 stage gastric cancer. *Cancer Res Treat* 2009;41:73-9.